Global Director of Vaccine Development
Location: Cleveland Clinic Florida Research & Innovation Center
The Ted Ross Lab focuses on developing vaccines against cancer and respiratory viruses, including influenza, COVID, respiratory syncytial virus, as well as HIV and arboviruses.
Ted Ross, PhD, is the Global Director of Vaccine Development at Cleveland Clinic.
Dr. Ross joined Cleveland Clinic from the University of Georgia where he was the Georgia Research Alliance Eminent Scholar of Infectious Diseases and director of the Center for Vaccines and Immunology. Prior to that, he was director of Vaccines and Viral Immunity at the Vaccine and Gene Therapy Institute of Florida.
Dr. Ross has published more than 230 peer-reviewed papers and book chapters on infectious disease and vaccine development. He participates in several vaccine working groups, including at the NIH, the U.S. Centers for Disease Control and Prevention and the World Health Organization. He is an editorial board member of Vaccine. He is the President of the International Society for Vaccines.
For his scientific achievements, Dr. Ross received the Phoenix Award for Outstanding Academic-Industry Partnership with Sanofi Pasteur in 2017 and the 2019 Golden Helix Award. In addition, he was honored with the 2020-2021 Charles Dobbins Award for Excellence in Service during the COVID-19 pandemic.
Dr. Ross completed his undergraduate and graduate studies in zoology and microbiology at the University of Arkansas. He received his doctorate from Vanderbilt University and was awarded the inaugural Sidney P. Colowick Award in Outstanding Graduate Research. Dr. Ross performed post-doctoral fellowships at Duke University and at Emory University.
Education & Fellowships
Fellowship - Emory University School of Medicine
Atlanta, GA USA
Fellowship - Duke University School of Medicine
Durham, NC USA
Graduate School - Vanderbilt University
Nashville, TN USA
Graduate School - University of Arkansas, Fayetteville
Fayetteville, AR USA
Undergraduate - University of Arkansas, Fayetteville
Fayetteville, AR USA
Dr. Ross’ cancer research focuses on vaccines against respiratory virus-induced diseases, including influenza, COVID, respiratory syncytial virus (RSV), as well as HIV and arboviruses such as Dengue, Zika, Chikungunya, and Rift Valley fever viruses. For his work in respiratory diseases and vaccines, he was awarded the Phoenix Award for Outstanding Academic-Industry Partnership with Sanofi Pasteur in 2017 and the 2019 Golden Helix Award. In addition, he was honored with the 2020-2021 Charles Dobbins Award for Excellence in Service during the COVID-19 pandemic.
Dr. Ross was appointed the Global Director of Vaccine Development at Cleveland Clinic which his team is focused on understanding the mechanisms to elicit broadly-reactive host responses against circulating and emerging pathogens. Dr. Ross leads a multi-disciplinary team of scientists and clinicians on the Ohio and Florida campuses with the goal to design and test novel vaccines.
Dr. Ross has several research projects related to respiratory viruses, such as influenza and coronaviruses. A major focus of Dr. Ross’ research is developing a more advanced and longer-lasting flu vaccine to protect against multiple strains of the virus. He is the Director of the Collaborative Influenza Vaccine Innovation Centers (CIVIC) network of the National Institutes of Health (NIH) for work on designing next generation, universal influenza vaccines. He also an investigator in the INCENTIVE program with the European Union and the government of India on the development of novel universal influenza and COVID-19 vaccines.
View publications for Ted Ross, PhD
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Our education and training programs offer hands-on experience at one of the nationʼs top hospitals. Travel, publish in high impact journals and collaborate with investigators to solve real-world biomedical research questions.Learn More
Elevated antibodies and immune cells associated with prior infection level out within six months of vaccination and need to be replenished with regular booster shots.
Next-generation vaccines are designed to protect against multiple viral strains and increase the time needed between booster shots.
In this newly created role, he will lead the development of novel vaccine platforms for a variety of infectious diseases, including influenza, HIV and COVID-19.